A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironmentsKevin C. Barry, Matthew F. Krummel, Amanda E. Nelson et al.|Nature Medicine|2018Cited by 1k
Discovering dominant tumor immune archetypes in a pan-cancer censusAlexis J. Combes, Sima P. Porten, Bushra Samad et al.|Cell|2021Cited by 172
CCR2 improves tumor directed CAR-T cell trafficking in ovarian cancerRaj Kumar, Oladapo Yeku|Frontiers in Pharmacology|2025Cited by 1